<DOC>
	<DOCNO>NCT02342665</DOCNO>
	<brief_summary>The primary objective study assess safety profile copanlisib recommend dose ( primary endpoint ) . The recommend dose copanlisib Japanese patient determine dose escalation/safety evaluation part</brief_summary>
	<brief_title>Japanese Phase Ib/II Copanlisib Relapsed , Indolent B-cell NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histologically confirm diagnosis indolent Bcell NHL , histological subtype limit follow : Follicular lymphoma ( FL ) grade 123a Small lymphocytic lymphoma ( SLL ) absolute lymphocyte count &lt; 5 x 109/L time diagnosis study entry Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia ( LPL/WM ) Marginal zone lymphoma ( MZL ) ( splenic , nodal , extranodal ) Relapsed refractory ≥ 2 prior line therapy ( refractory define respond standard regimen progress within 6 month last course standard regimen ) . Patients must previously receive rituximab alkylating agent ( ) . Japanese patient ≥ 20 year age ECOG performance status ≤ 2 ( Eastern Cooperative Oncology Group : ECOG ) Life expectancy least 3 month Adequate bone marrow , liver renal function assess within 7 day start study treatment Left ventricular ejection fraction ( LVEF ) ≥ low limit normal ( LLN ) Institution Availability fresh archival tumor tissue Uncontrolled hypertension ( blood pressure ≥ 150/90 mmHg , define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 90 mmHg , despite optimal medical management ) Patients evidence history bleed diathesis . Any hemorrhage bleeding event ≥ CTCAE Grade 3 ( NCICTC version 4.0 ) within 4 week start study medication ( CTCAE : Common Terminology Criteria Adverse Events , NCI : National Cancer Institute ) . History concurrent condition interstitial lung disease severely impaired pulmonary function Unresolved toxicity high CTCAE grade 1 attributed prior therapy/procedure exclude alopecia . Prior treatment PI3K inhibitor Systemic corticosteroid therapy ( ongoing ) Type I II diabetes mellitus HbA1c &gt; 8.5 % fast plasma glucose &gt; 160 mg/dL Screening Known history human immunodeficiency virus ( HIV ) infection . Hepatitis B C require treatment Cytomegalovirus ( CMV ) PCR positive baseline Known lymphomatous involvement central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non Hodgkin 's Lymphomas</keyword>
</DOC>